Moderna’s Booster Shots<br />Appear ‘Effective’ at Protecting<br />Against COVID-19 Variants.<br />Moderna’s Booster Shots<br />Appear ‘Effective’ at Protecting<br />Against COVID-19 Variants.<br />On May 5, Moderna reported results from its ongoing<br />studies involving booster doses for its COVID-19 vaccine. .<br />Current research suggests that people who've received Moderna's existing vaccine have a diminished response to variants. .<br />The drugmaker disclosed data from<br />two of its three strategies. .<br />One strategy involves administering a third shot containing<br />half the dosage of its current vaccine. .<br />The other involves administering a third dose<br />containing a completely new vaccine developed specifically<br />to protect against the South Africa variant. .<br />According to Moderna, both boosters displayed<br />protection against variants that was “similar to or higher”<br />than the peak protection its original vaccine offered<br />against the first strain of COVID-19.<br />In particular, the specialized-vaccine<br />booster appeared to be “more effective” at protecting<br />against variants than the half-dosage booster. .<br />“Solicited adverse events” following<br />the booster shots were found to be<br />“mild” or “moderate.”.<br />The most common side effects were<br />injection site pain, fatigue, headache,<br />muscle pain and joint pain.<br />Moderna’s Phase 2 study is ongoing.<br />Phase 3 data is expected to be<br />released in the coming months.
